A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

This is a Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of
Durvalumab in Combination With Novel Oncology Therapies, With or Without Chemotherapy, for
First-Line Stage IV Non Small Cell Lung Cancer (NSCLC).

Inclusion Criteria:

- Histologically or cytologically documented Stage IV NSCLC not amenable to curative
surgery or radiation

- No prior chemotherapy or any other systemic therapy for metastatic NSCLC

- Prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for
advanced disease are eligible, if progression has occurred >12 months from end of last
therapy

- Known tumor PD-L1 status

- WHO/ECOG status at 0 or 1 at enrollment

- Life expectancy of at least 12 weeks

Exclusion Criteria:

- Active or prior documented autoimmune or inflammatory disorders

- History of active primary immunodeficiency

- Any prior chemotherapy or any other systemic therapy for metastatic NSCLC

- Untreated CNS metastases